ENANTA PHARMACEUTICALS INC — Director's Dealing 2021

Oct 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2021-10-08

Reporting Person: Adda Nathalie (Sr. VP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-08	Common Stock	M	13453	$43.46	Acquired	40397	Direct
2021-10-08	Common Stock	S	13453	$70.091	Disposed	26944	Direct
2021-10-11	Common Stock	M	4047	$43.46	Acquired	30991	Direct
2021-10-11	Common Stock	S	4047	$70.3448	Disposed	26944	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-08	Stock Option (Right to Buy)	$43.46	M	13453	Disposed	2025-06-29	Common Stock (13453)	Direct
2021-10-11	Stock Option (Right to Buy)	$43.46	M	4047	Disposed	2025-06-29	Common Stock (4047)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive.

F4: 100% of the shares subject to the option are fully vested and exercisable.